Synergy Pharmaceuticals

Gastro-intestinals

Synergy Pharmaceuticals

USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) is a biopharmaceutical company dedicated to developing new drugs to treat patients with gastrointestinal disorders and diseases.

USA-based biopharma groups Synergy Pharmaceuticals (Nasdaq: SGYP) is a biopharmaceutical company dedicated to developing new drugs to treat patients with gastrointestinal disorders and diseases.

Based in New York, Synergy is led by a seasoned team of scientists, clinicians and executives with extensive experience in the biopharmaceutical industry. The company'’s lead investigational drug, plecanatide, is in late-stage clinical development for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

CIC and IBS-C are two of the most common gastrointestinal disorders globally, and are significant drivers of both direct and indirect healthcare costs. Many doctors and their patients are deeply dissatisfied with current available treatment options. A Phase IIb clinical trial to evaluate plecanatide in the treatment of IBS-C began in December 2012, and is expected to be completed in early 2014.

In addition to plecanatide, Synergy’'s clinical development pipeline includes a next-generation GC-C agonist, known as SP-333, in clinical development for the treatment of ulcerative colitis. A Phase I single ascending dose safety study of SP-333 was completed in late 2012; in January 2013, a Phase I multiple dose safety study was begun in healthy volunteers.


Latest Articles

Latest News

Who's Who

Company Spotlight

Fibrotech

Fibrotech

Back to top